Georgia's Online Cancer Information Center

Find A Treatment Site

Atlanta Cancer Care - Alpharetta

Atlanta Cancer Care is a medical oncology practice with ten physicians practicing at six offices located around the metropolitan Atlanta area. Atlanta Cancer Care is accredited by the American College of Radiology (ACR). The Atlanta Cancer Care practice is also a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers. Atlanta Cancer Care provides laboratory, infusion, supportive care, and diagnostic services in all of its offices. The majority of chemotherapy treatment is provided in the Atlanta Cancer Care office, rather than the hospital. Atlanta Cancer Care participates in clinical trials which use chemotherapy drugs, and/or other drugs which affect cancer cells. Pain management, evaluation for clinical trials, behavioral health, nutrition, home health and hospice, and financial counseling services are all provided and/or coordinated by the Atlanta Cancer Care staff. Atlanta Cancer Care strives to treat the whole person and family including emotional, spiritual, nutritional, and pain management needs.

Treatment Sites in Georgia

Primary Location

3400 C Old Milton Parkway
Suite 400
Alpharetta, GA 30005
770-740-9664 (p)
770-740-9359 (f)
www.atlantacancercare.com

driving directions

Clinical Trials in Georgia

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Cancer Type: Lung Cancer

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Cancer Type: Prostate Cancer , Unknown Primary

A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients
Cancer Type: Breast Cancer, Unknown Primary

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Cancer Type: Lung Cancer

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Cancer Type: Unspecified

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I / II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4 / RTOG-3515)
Cancer Type: Lung Cancer

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Cancer Type: Ovarian Cancer

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Cancer Type: Breast Cancer

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Cancer Type: Melanoma, Unknown Primary

A Randomized, Double-Blind, Phase III Trial of Paclitaxel / Trastuzumab / Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
Cancer Type: Unspecified

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer Type: Lung Cancer

Cancer Moonshot Biobank Research Protocol
Cancer Type: Unspecified

Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Cancer Type: Brain Cancer

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary

INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction / Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
Cancer Type: Lung Cancer

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Cancer Type: Unspecified

Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Cancer Type: Brain Cancer

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Cancer Type: Breast Cancer, Unknown Primary

The National Myelodysplastic Syndromes (MDS) Study
Cancer Type: Myelodysplastic Syndromes (MDS)
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofitthat leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.